Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Suzhou Ribo Life Science Co., Ltd.
蘇州瑞博生物技術股份有限公司
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 6938)

VOLUNTARY ANNOUNCEMENT

PHASE I CLINICAL TRIAL APPLICATION SUBMISSION OF NOVEL DUAL TARGETING SIRNA SR122 FOR TREATMENT OF MIXED DYSLIPIDEMIA AND SEVERE HYPERTRIGLYCERIDEMIA

This announcement is made by Suzhou Ribo Life Science Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to provide shareholders of the Company (the "**Shareholders**") and potential investors with an update on the Group's research and development progress.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce the submission of the phase I clinical trial application (the "**CTA**") in the European Union for the Company's self-developed product SR122, a dual GalNAc-conjugated siRNA therapy for treatment of dyslipidemia, including severe hypertriglyceridemia (sHTG) and mixed dyslipidemia.

The CTA submission represents a further enhancement of the Company's lipid pipeline strategy and an important step in consolidating its leading position in the field of lipid disorders, as the Company continues to advance the phase II clinical studies of RBD5044, its core lipid-lowering asset and the world's second most advanced ApoC3-targeting siRNA therapy, in Europe and China.

SR122 simultaneously targets both ApoC3 and PCSK9, the two clinically validated targets which play complementary roles in lipid metabolism. By addressing both triglyceride-rich lipoproteins and low-density lipoprotein cholesterol (LDL-C), SR122 has the potential to offer a differentiated therapeutic approach that provides superior synergy in severe hypertriglyceridemia with durable improvements across multiple lipid parameters and cardiometabolic risk factors and represent a step change in patient risk management through inhibition of complementary mechanisms.

Dyslipidemia remains a major global health challenge and a key driver of cardiovascular disease, which is the leading cause of death worldwide. Despite currently available lipid-lowering therapies, patients with mixed dyslipidemia often continue to face substantial residual cardiovascular risk, while patients with severe hypertriglyceridemia are also at an increased risk of acute pancreatitis.

The phase I clinical trial is a randomized, placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneously administered SR122 in healthy participants. The study will provide the first clinical evaluation of SR122's dual-targeting approach in humans and generate key data to support its further development.

SR122 injection may not ultimately be successfully developed and commercialized. Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Suzhou Ribo Life Science Co., Ltd.
LIANG Zicai
Chairman

Hong Kong, November 10, 2026

As of the date of this announcement, the executive Directors are Dr. LIANG Zicai, Dr. GAN Liming and Dr. ZHANG Hongyan, the non-executive Directors are Dr. QI Fei, Mr. LI Dongfang and Mr. LI Yuhui, and the independent non-executive Directors are Dr. YU Xuefeng, Mr. MA Chaosong and Mr. WANG Ruiping.